Clinical trial · Observational
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
NCT01264822CI-TRIAL-00026159completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rabeprazole Sodium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Treatment Arm 1 Rabeprazole Sodium
- interventionNames
- Drug: Rabeprazole Sodium
Primary outcomes (2)
- measure
- Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori
- timeFrame
- Every 3 months within the 1st year and every 6 months
- measure
- Transition rate to secondary therapy for eradication of Helicobacter pylori
- timeFrame
- Every 6 months within the 1st year and every 12 months as needed
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: * gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphoma with Helicobacter pylori positive * The stages of MALT lymphoma are Lugano International Conference classification Stage I or II 1 and Wotherspoon grade 4 or 5 Exclusion criteria: * With diffuse large B-cell lymphoma * Have been treated to gastric mucosa-associated lymphoid tissue (MALT) lymphoma * Corresponding to contraindication of each drug
References
Publications (0)
Data not yet available
No reference posted for this study.